fulvestrant has been researched along with saracatinib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez, EA; Azzam, D; Chen, Y; Guggisberg, N; Hennessy, BT; Jordà , M; Ju, Z; Slingerland, JM; Wander, SA | 1 |
| Azzam, D; da Silva, T; Gilbert, CA; Hevia-Paez, P; Ince, TA; Levin, ER; Lu, Y; Mills, GB; Pedram, A; Rabinovich, B; Reis, IM; Simpkins, F; Slingerland, JM; Sun, J; Ullmer, W; Verhaak, RG; Xu, XX; Yang, JY | 1 |
| Fu, J; Gou, W; Han, X; Li, L; Li, X; Yang, T; Zhang, Y | 1 |
3 other study(ies) available for fulvestrant and saracatinib
| Article | Year |
|---|---|
Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; G1 Phase; Humans; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Quinazolines; src-Family Kinases; Tamoxifen; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzodioxoles; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Ovarian Neoplasms; Protein Binding; Protein Transport; Quinazolines; Receptors, Estrogen; src-Family Kinases; Xenograft Model Antitumor Assays | 2012 |
An ovarian cancer model with positive ER: Reversion of ER antagonist resistance by Src blockade.
Topics: Adult; Aged; Antineoplastic Agents; Benzodioxoles; Cell Cycle; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Ovarian Neoplasms; Quinazolines; src-Family Kinases; Survival Analysis | 2014 |